Cited by 299Lipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease PrognosisCardiovascular Health and Risk Factors

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study

Open access

Wilson, Peter W.F., Pencina, Michael, Jacques, Paul, Selhub, Jacob, D'Agostino, Ralph, O'Donnell, Christopher J.·2008·Circulation: Cardiovascular Quality and Outcomes

DOI 10.1161/circoutcomes.108.831198PMC PMC3033831

Open this paper in CoChat — free account

Abstract

Background— The relationship of circulating levels of high-sensitivity C-reactive protein (CRP) with cardiovascular disease (CVD) risk, particularly with consideration of effects at intermediate levels of risk, has not been fully assessed. Methods and Results— Among 3006 offspring participants in the Framingham Heart Study free of CVD (mean age, 46 years at baseline), there were 129 hard coronary heart disease (CHD) events and 286 total CVD events during 12 years of follow-up. Cox regression, discrimination with area under the receiver operating characteristic curve, and net reclassification improvement were used to assess the role of CRP on vascular risk. In an age-adjusted model that included both sexes, the hazard ratios for new hard CHD and total CVD were significantly associated with higher CRP levels. Similar analyses according to increasing homocysteine level showed significant protective associations for hard CHD but not for total CVD. In multivariable analyses that included age, sex, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, current smoking, hypertension treatment, and homocysteine, the log CRP level remained significantly related to development of hard CHD and total CVD and provided moderate improvement in the discrimination of events. The net reclassification improvement when CRP was added to traditional factors was 5.6% for total CVD ( P =0.014) and 11.8% for hard CHD ( P =0.009). Conclusions— Circulating levels of CRP help to estimate risk for initial cardiovascular events and may be used most effectively in persons at intermediate risk for vascular events, offering moderate improvement in reclassification of risk.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circoutcomes.108.831198

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Self-citation
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Self-citation
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Self-citation
Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION
PearsonT, A., MensahG, A., & AlexanderR, W. (2003) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200305000-00016 · Cited by 2,937
Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction
Cook, N. R. (2007) · Circulation · doi:10.1161/circulationaha.106.672402 · Cited by 2,167

Show all 38 references

Research works printed but not linked: 6

10.1161/circ.97.18.1837 · DOI
10.1161/res.89.9.763 · DOI
10.1161/circ.100.3.230 · DOI
10.1161/circ.96.1.44 · DOI
10.1161/circ.104.15.1863 · DOI
Assmann G Schulte H Oberwittler W. New aspects in the prediction of coronary artery disease: the Prospective Cardiovascular Munster Study. In: Fidge NH Nestel PJ eds. Atherosclerosis VII. Amsterdam: Elsevier; 1986: 19–24.

Sorted by citations

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,865
Untitled work
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,435
A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
Tangri, N. (2011) · JAMA · doi:10.1001/jama.2011.451 · Cited by 1,390
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals
Yeboah, J., McClelland, R. L., Polonsky, T. S., Burke, G. L., Sibley, C. T., O’Leary, D., Carr, J. J., Goff, D. C., Greenland, P., & Herrington, D. M. (2012) · JAMA · doi:10.1001/jama.2012.9624 · Cited by 1,122
Predicting the 30-Year Risk of Cardiovascular Disease
Pencina, M. J., D’Agostino, R. B., Larson, M. G., Massaro, J. M., & Vasan, R. S. (2009) · Circulation · doi:10.1161/circulationaha.108.816694 · Cited by 885
Self-citation
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Coronary Risk Stratification, Discrimination, and Reclassification Improvement Based on Quantification of Subclinical Coronary Atherosclerosis
Erbel, R. M., Möhlenkamp, S., Moebus, S., Schmermund, A., Lehmann, N., Stang, A., Dragano, N., Grönemeyer, D. H. W., Seibel, R. M. M., Kälsch, H., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.030 · Cited by 783
Plasma Proteome Profiling to Assess Human Health and Disease
Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., & Mann, M. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.015 · Cited by 734
“Both are correlated with inflammatory states, and chronic elevation is strongly associated with increased risk for future cardiovascular events (Hua et al., 2009; Wilson et al., 2008).”
Background
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 702
C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force
Buckley, D., Fu, R. F., Freeman, M., Rogers, K. R., & Helfand, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-7-200910060-00009 · Cited by 561
High-Sensitivity C-Reactive Protein and Cardiovascular Disease
Yousuf, O. K., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., Blumenthal, R. S., & Budoff, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.016 · Cited by 505
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 502
Obesity and Inflammation: Epidemiology, Risk Factors, and Markers of Inflammation
Rodríguez-Hernández, H., Simental‐Mendía, L. E., Ramírez, G. R., & Reyes-Romero, M. A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/678159 · Cited by 509
“Thus, supported by a large number of observational studies and meta-analyses, CRP is considered as a mediator of cardiovascular disease [116], independently of age, smoking, cholesterol levels, blood pressure, and diabetes among others traditional risk factors evaluated in the clinical setting [117].”
Background
Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures
Cook, N. R., & Ridker, P. M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00007 · Cited by 458
“Other studies have presented similar results for some of these variables (7, 9, 22, 23).”
Result
Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk
Cooney, M. T., Dudina, A. L., & Graham, I. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.020 · Cited by 436
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Coronary Calcium Score Improves Classification of Coronary Heart Disease Risk in the Elderly
Elias‐Smale, S. E., Vliegenthart, R., Koller, M., Kavousi, M., van Rooij, F. J. A., Hunink, M. G. M., Steyerberg, E. W., Albert Hofman, D., Oudkerk, M., & Witteman, J. C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.029 · Cited by 369
Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification: A Cohort Study
Kavousi, M., Elias-Smale, S., Rutten, J. H. W., Leening, M. J. G., Vliegenthart, R., Verwoert, G. C., Krestin, G. P., Oudkerk, M., de Maat, M. P. M., Leebeek, F. W. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00006 · Cited by 360
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Measurement of Arterial Activity on Routine FDG PET/CT Images Improves Prediction of Risk of Future CV Events
Figueroa, A. L., Abdelbaky, A., Truong, Q. A., Corsini, E. M., MacNabb, M. H., Lavender, Z. R., Lawler, M. A., Grinspoon, S. K., Brady, T. J., Nasir, K., et al. (2013) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2013.08.006 · Cited by 336
“6% in the Framingham Heart Study [3] and 5.”
Background
Statistical methods for assessment of added usefulness of new biomarkers
Pencina, M. J., D’Agostino, R. B., & Vasan, R. S. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.340 · Cited by 335
Self-citation
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
“Most algorithms estimate 10-year risk for CHD or ASCVD.”
Background
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 319
Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
Wong, N. D., Budoff, M. J., Ferdinand, K. C., Graham, I. M., Michos, E. D., Reddy, T. K., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100335 · Cited by 327
Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction
Wang, T. J. (2011) · Circulation · doi:10.1161/circulationaha.109.912568 · Cited by 299
Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Ezaz, G. Z., Long, J. B., Gross, C. P., & Chen, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000472 · Cited by 278
Cardiorespiratory Fitness and Classification of Risk of Cardiovascular Disease Mortality
Gupta, S. K., Rohatgi, A. K., Ayers, C. R., Willis, B. L., Haskell, W. L., Khera, A., Drazner, M. H., de Lemos, J. A., & Berry, J. D. (2011) · Circulation · doi:10.1161/circulationaha.110.003236 · Cited by 242
Prognostic Value of Stress Myocardial Perfusion Positron Emission Tomography
Dorbala, S., Carli, M. F. D., Beanlands, R. S., Merhige, M. E., Williams, B. A., Veledar, E., Chow, B. J. W., Min, J. K., Pencina, M. J., Berman, D. S., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.043 · Cited by 233
“Risk reclassification is a relatively novel concept that has been applied to the assessment of other risk markers such as calcium score(13), c-reactive protein(14 ) and more recently reported with SPECT MPI (15) and coronary flow reserve by quantitative PET MPI.”
MethodSelf-citation
C-reactive protein is a mediator of cardiovascular disease
Bisoendial, R. J., Boekholdt, S. M., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq238 · Cited by 230
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Cardiovascular Risk-Estimation Systems in Primary Prevention: Do They Differ? Do They Make a Difference? Can We See the Future?
Cooney, M. T., Dudina, A., D'Agostino, R., & Graham, I. M. (2010) · Circulation · doi:10.1161/circulationaha.109.852756 · Cited by 222
Self-citation
Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Lin, J. S., Evans, C. V., Johnson, E., Redmond, N., Coppola, E. L., & Smith, N. (2018) · JAMA · doi:10.1001/jama.2018.4242 · Cited by 216
C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
Homocysteine and Reclassification of Cardiovascular Disease Risk
Veeranna, V., ZALAWADIYA, S. K., Niraj, A., Pradhan, J., Ference, B. A., Burack, R. C., Jacob, S., & Afonso, L. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.028 · Cited by 213
“Some of these emerging markers, such as C-reactive protein (CRP), an inflammatory biomarker (6,7); concentration of coronary artery calcium (CAC) (8); and level of homocysteine (Hcy), an amino acid that can be easily and reliably measured in human plasma (5,9), have shown promise (5,10,11).”
BackgroundMethod
Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice
Avan, A., Tavakoly Sany, S. B., Ghayour‐Mobarhan, M., Rahimi, H. R., Tajfard, M., & Ferns, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26791 · Cited by 182
“…p at ie n t w it h lu p u s n ep h ri ti s (C o n ti n u es ) acute‐phase stimulus (e.g., acute inflammation) within 6 hr, plasma CRP levels increase from 50 µg/L to more than 500 mg/L within 48 hr, that is, 10,000‐fold 26 (Pepys & Hirschfield, 2003; Shrivastava et al., 2015; Wilson et al., 2008).”
Background
Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: Insights from the National Health and Nutrition Examination Survey-III
Shah, N. N., Parikh, V. K., Patel, N., Patel, N., Badheka, A., Deshmukh, A. J., Rathod, A. D., & Lafferty, J. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.019 · Cited by 184
“Prior studies have shown that hsCRP significantly reclassifies FRS with a NRI of around 5–8% [77,78].”
Background
Pathophysiology of coronary artery disease leading to acute coronary syndromes
Ambrose, J. A., & Singh, M. (2015) · F1000Prime Reports · doi:10.12703/p7-08 · Cited by 175
“Traditional risk factor scores are inadequate because, while those at highest risk are more likely to develop adverse events, most adverse events on followup do not occur in these patients but in the middle- or lower-risk populations, which are much larger in numbers than the high-risk [19,20].”
Background
Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients
Rosenberg, S. J., Elashoff, M. R., Beineke, P., Daniels, S. E., Wingrove, J. A., Tingley, W. G., Sager, P. T., Sehnert, A. J., Yau, M., Kraus, W. E., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-7-201010050-00005 · Cited by 173
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
“It should be stressed, however, that although many other risk factors have been identified, their contribution is generally very modest to both absolute CV risk estimations and in terms of reclassification of an individual to another risk category [67] (Table 4).”
Geriatric Conditions and Subsequent Mortality in Older Patients With Heart Failure
Chaudhry, S. I., Wang, Y., Gill, T. M., & Krumholz, H. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.066 · Cited by 155
Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis
Elkhawad, M., Rudd, J. H. F., Sarov‐Blat, L., Cai, G., Wells, R., Davies, C., Collier, D., Marber, M. S., Choudhury, R. P., Fayad, Z. A., et al. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2012.02.016 · Cited by 152
The BioImage Study: Novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease—study design and objectives
Muntendam, P., McCall, C. J., Sanz, J., Falk, E., & Fuster, V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.02.021 · Cited by 149
Novel biomarkers of cardiovascular disease: Applications in clinical practice
Lyngbakken, M. N., Myhre, P. L., Røsjø, H. R., & Omland, T. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1525335 · Cited by 155
Assessing salivary C-reactive protein: Longitudinal associations with systemic inflammation and cardiovascular disease risk in women exposed to intimate partner violence
Out, D., Hall, R. J., Granger, D. A., Page, G. G., & Woods, S. J. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.01.019 · Cited by 140
“Mildly elevated CRP in the circulation is associated with chronic inflammation and a heightened risk for CVD through its involvement in atherosclerosis (e.g., Melander et al., 2009; Ridker et al., 1998; Wilson et al., 2008; for reviews see Bisoendial et al., 2010; Pearson et al., 2003), whereas markedly high concentra…”
Background
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0120 · Cited by 152
Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease
Hayward, R. A., Krumholz, H. M., Zulman, D. M., Timbie, J. W., & Vijan, S. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00004 · Cited by 130
“For example, although LDL cholesterol has generally not been found to be an independent CAD risk factor when other lipid measures are considered (20, 25, 46), increasing evidence shows that C-reactive protein is an independent marker, and it may help identify intermediate-risk persons who should or should not receive…”
Background
Inflammation in Coronary Artery Disease
Christodoulidis, G., Vittorio, T. J., Fudim, M., Lerakis, S., & Kosmas, C. E. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000006 · Cited by 128
The influence of hip circumference on the relationship between abdominal obesity and mortality
Cameron, A. J., Magliano, D. J., Shaw, J. E., Zimmet, P., Carstensen, B., Alberti, K. G. M. M., Tuomilehto, J. O., Barr, E., Pauvaday, V., Kowlessur, S., et al. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr198 · Cited by 124
C-Reactive Protein Promotes Cardiac Fibrosis and Inflammation in Angiotensin II–Induced Hypertensive Cardiac Disease
Zhang, R., Zhang, Y. Y., Huang, X. R., Wu, Y., Chung, A. C. K., Wu, E. X., Szalai, A. J., Yu, W. B. C., Lau, C., & Lan, H. Y. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.140608 · Cited by 117
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
KONES, R. J. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10812 · Cited by 112
The Potential Benefit of Monitoring Oxidative Stress and Inflammation in the Prevention of Non-Communicable Diseases (NCDs)
Seyedsadjadi, N., & Grant, R. (2020) · Antioxidants · doi:10.3390/antiox10010015 · Cited by 108
Comorbidity in inflammatory bowel disease
López–Sanromán, A. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i22.2723 · Cited by 102
The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines
Mora, S., Musunuru, K., & Blumenthal, R. S. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.109728 · Cited by 100
Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator
Khera, A., Budoff, M. J., O’Donnell, C. J., Ayers, C. R., Locke, J. P., de Lemos, J. A., Massaro, J. M., McClelland, R. L., Taylor, A. J., & Levine, B. D. (2018) · Circulation · doi:10.1161/circulationaha.118.033505 · Cited by 101
“High-density lipoprotein cholesterol, mg/dL* 51 (15) 50 (15) 51 (15) 53 (15) 54 (17)”
Self-citation
Critical appraisal of inflammatory markers in cardiovascular risk stratification
Krintus, M., Koziński, M., Kubica, J., & Sypniewska, G. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.913549 · Cited by 91
DNA methylation biomarkers of myocardial infarction and cardiovascular disease
Fernández‐Sanlés, A., Sayols-Baixeras, S., Subirana, I., Sentı́, M., Pérez-Fernández, S., Moura, M. D. C., Esteller, M., Marrugat, J., & Elosúa, R. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01078-6 · Cited by 84
The role of n − 6 and n − 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease
Monteiro, J., Leslie, M. A., Moghadasian, M. H., Arendt, B. M., Allard, J. P., & David, W. L. (2014) · Food & Function · doi:10.1039/c3fo60551e · Cited by 84
Detection of Homocysteine and C-Reactive Protein in the Saliva of Healthy Adults: Comparison with Blood Levels
Dillon, M. C., Opris, D., Kopanczyk, R., Lickliter, J., Cornwell, H. N., Bridges, E. G., Nazar, A. M., & Bridges, K. G. (2010) · Biomarker Insights · doi:10.4137/bmi.s5305 · Cited by 81
Risk prediction in cardiovascular disease: The prognostic significance of endothelial dysfunction
Martin, B., & Anderson, T. J. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)71049-9 · Cited by 79
Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease
Mack, M. C., & Gopal, A. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.002 · Cited by 78
Heat therapy reduces sympathetic activity and improves cardiovascular risk profile in women who are obese with polycystic ovary syndrome
Ely, B. R., Francisco, M. A., Halliwill, J. R., Bryan, S. D., Comrada, L. N., Larson, E. A., Brunt, V. E., & Minson, C. T. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00078.2019 · Cited by 74
Cardiovascular risk assessment - From individual risk prediction to estimation of global risk and change in risk in the population
Batsis, J. A., & López-Jiménez, F. A. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-29 · Cited by 77
“Yet studies have shown a minimal incremental value of adding new biomarkers to existing prediction models in a recent study by the Framingham group [21].”
Background
Identifying novel biomarkers for cardiovascular disease risk prediction
Ge, Y., & Wang, T. J. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02589.x · Cited by 71
C - reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis
Chandrashekara, S. (2014) · Internet Journal of Rheumatology and Clinical Immunology · doi:10.15305/ijrci/v2is1/117 · Cited by 65
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 67
Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: Results from a multi-ethnic cohort
Veeranna, V., ZALAWADIYA, S. K., Niraj, A., Kumar, A., Ference, B. A., & Afonso, L. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.034 · Cited by 65
Classical and Novel Biomarkers for Cardiovascular Risk Prediction in the United States
Folsom, A. R. (2013) · Journal of Epidemiology · doi:10.2188/jea.je20120157 · Cited by 65
Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk
Ridker, P. M., MacFadyen, J. G., Nordestgaard, B. G., Köenig, W., Kastelein, J. J. P., Genest, J. J., & Glynn, R. J. (2010) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.938118 · Cited by 64
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials
Braunwald, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr310 · Cited by 64
Impaired retinal vasodilator responses in prediabetes and type 2 diabetes
Lott, M. E. J., Slocomb, J. E., Shivkumar, V., Smith, B., Quillen, D. A., Gabbay, R. A., Gardner, T. W., & Bettermann, K. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12129 · Cited by 66
“2009) and heart disease (Wilson et al. 2008; Buckley et al. 2009) and risk of a having a myocardial infarction (Ridker 2004).”
Background
New and Emerging Risk Factors for Coronary Heart Disease
Akhabue, E., Thiboutot, J. P., Cheng, J.-W., Lerakis, S., Vittorio, T. J., Christodoulidis, G., Grady, K. M., & Kosmas, C. E. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828aab45 · Cited by 64
High-sensitivity C reactive protein and risk of cardiovascular disease in China-CVD study
Dong, Y., Wang, X., Zhang, L., Chen, Z., Zheng, C., Wang, J., Kang, Y., Shao, L., Tian, Y., & Wang, Z. (2018) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2018-211433 · Cited by 60
Cardiovascular Disease Prediction by Machine Learning Algorithms Based on Cytokines in Kazakhs of China
Jiang, Y., Zhang, X., Ma, R., Wang, X., Liu, J., Keerman, M., Yan, Y., Ma, J., Song, Y., Zhang, J., et al. (2021) · Clinical Epidemiology · doi:10.2147/clep.s313343 · Cited by 63
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study
Rana, J. S., Cote, M., Després, J., Sandhu, M. S., Talmud, P. J., Ninio, E., Wareham, N. J., Kastelein, J. J. P., Zwinderman, A. H., Khaw, K., et al. (2009) · Heart · doi:10.1136/hrt.2009.170134 · Cited by 58
C-reactive protein is a bystander of cardiovascular disease
Anand, S. S., & Yusuf, S. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq242 · Cited by 56
Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease
Mack, M. C., & Gopal, A. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.003 · Cited by 59
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial
Sever, P., Poulter, N. R., Chang, C., Hingorani, A. D., Thom, S., Hughes, A. D., Welsh, P. I., Sattar, N. A., & on behalf of the ASCOT Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr262 · Cited by 56
“These findings are broadly in line with other prospective studies showing statistically significant, but modest absolute improvements with the use of C-reactive protein in clinical risk prediction.(22,23)”
Result
Serum C-reactive protein level and prediabetes in two Asian populations
Sabanayagam, C., Shankar, A., Lim, S. C., Lee, J., Tai, E. S., & Wong, T. Y. (2011) · Diabetologia · doi:10.1007/s00125-011-2052-5 · Cited by 52
“We repeated the multivariable model in Table 2: (1) using quartiles of CRP (<0.4, 0.4–1.0, 1.1–2.6, >2.6 mg/l); (2) after excluding participants with hsCRP levels suggestive of clinical inflammation (>10 mg/l); and (3) after excluding participants with history of CVD.”
BackgroundInfluential
C-reactive protein and cardiovascular risk in the general population
Kurt, B., Reugels, M., Schneider, K. M., Spießhoefer, J., Milzi, A., Gombert, A., Fordyce, C. B., Wenzl, F. A., Pagidipati, N. J., Rocha, V. Z., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf937 · Cited by 53
CVD screening in low-risk, asymptomatic adults: clinical trials needed
Polonsky, T. S., & Greenland, P. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.114 · Cited by 50
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis
Ortíz, A., Massy, Z. A., Fliser, D., Lindholm, B., Więcek, A., Martínez‐Castelao, A., Covic, A. C., Goldsmith, D. J. A., Süleymanlar, G., London, G. M., et al. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.170 · Cited by 50
“002% discrimination power to predictions made on the basis of Framingham risk factors, but was useful for risk reclassification of coronary heart disease events”
Elevated Pulmonary Artery Systolic Pressure Predicts Heart Failure Admissions in African Americans
Choudhary, G., Jankowich, M. D., & Wu, W. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001366 · Cited by 49
“8% when added to a multivariable prediction model in the Framingham Offspring cohort in predicting coronary heart disease events).(28) Future studies will be needed to determine if PASP and N-terminal prohormone of brain natriuretic peptide have overlapping or synergistic effects when added together to the ARIC model.”
Method
High-Sensitive C-Reactive Protein: Universal Prognostic and Causative Biomarker in Heart Disease?
Rietzschel, E. R., & Buyzere, M. D. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.11.108 · Cited by 49
Association of Serum Procalcitonin With Cardiovascular Prognosis in Coronary Artery Disease
Sinning, C., Sinning, J., Schulz, A., Schnabel, R. B., Lubos, E., Wild, P. S., Papassotiriou, J., Bergmann, A., Blankenberg, S., Münzel, T. F., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-0638 · Cited by 47
The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial
Abd, T. T., Eapen, D. J., Bajpai, A., Goyal, A., Dollar, A. L., & Sperling, L. S. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0164-5 · Cited by 47
“7% for CVD and 24% for the hard endpoints of CHD [35].”
BackgroundMethodInfluential
The Emerging Role of Inflammation in Cardiovascular Disease
Martinez, B. K., & White, C. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018765939 · Cited by 50
Risk and the Physics of Clinical Prediction
McEvoy, J. W., Diamond, G. A., Detrano, R., Kaul, S., Blaha, M. J., Blumenthal, R. S., & Jones, S. R. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.01.418 · Cited by 46
C-Reactive Protein and Colorectal Cancer Mortality in U.S. Adults
Goyal, A., Terry, M. B., Jin, Z., & Siegel, A. B. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0577 · Cited by 45
Early identification of atherosclerotic disease by noninvasive imaging
Fuster, V., Lois, F., & Franco, M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.54 · Cited by 46
Improved Near-Term Coronary Artery Disease Risk Classification With Gated Stress Myocardial Perfusion SPECT
Shaw, L. J., Wilson, P. W. F., Hachamovitch, R., Hendel, R. C., Borges‐Neto, S., & Berman, D. S. (2010) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2010.09.008 · Cited by 43
“Several eports have noted this as an effective method for valuating the added value of high sensitivity -reactive protein beyond that of the Framingham isk score (12,13,19,20).”
MethodSelf-citation
Predicting the risk of coronary heart disease. II: The role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction
Dent, T. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.021 · Cited by 46
Sarcopenic obesity associated with high-sensitivity C-reactive protein in age and sex comparison: a two-center study in South Korea
Park, C., Do, J. G., Lee, Y., & Yoon, K. J. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021232 · Cited by 42
Association of Physical Activity and Inflammation With All-Cause, Cardiovascular-Related, and Cancer-Related Mortality
Lee, J., Ryu, S., Cheong, E., & Sung, K. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.08.003 · Cited by 40
Methods for evaluating novel biomarkers - a new paradigm
Cook, N. R. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02469.x · Cited by 39
Prognostic Importance of C‐Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study
Cardoso, C. R. L., Leite, N. C., & Salles, G. F. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004554 · Cited by 34
Plasma miRNAs improve the prediction of coronary atherosclerosis in patients with rheumatoid arthritis
Ormseth, M. J., Solus, J. F., Sheng, Q., Chen, S., Ye, F., Wu, Q., Oeser, A. M., Allen, R. M., Raggi, P., Vickers, K. C., et al. (2021) · Clinical Rheumatology · doi:10.1007/s10067-020-05573-8 · Cited by 36
“799 for total cardiovascular disease [23].”
Association Between the Neutrophil Percentage-to-Albumin Ratio and Outcomes in Cardiac Intensive Care Unit Patients
Wang, X., Wang, J., Wu, S., Ni, Q., & Chen, P. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s328882 · Cited by 36

Authors: Wilson, P. W. F., Pencina, M., Jacques, P., Selhub, J., D'Agostino, R., & O'Donnell, C. J.
Affiliations: Boston University (US)
From EPICORE (P.W.F.W.), Emory University School of Medicine, and the Atlanta VAMC Epidemiology and Genetics Section, Atlanta, Ga; National Heart, Lung, and Blood Institute (C.J.O.D.); National Heart, Lung and Blood Institute’s Framingham Heart Study (M.P., R.D.A., C.J.O.D.), Framingham Mass; Department of Mathematics (M.P., R.D.A.), Boston University, Boston, Mass; Tufts USDA Nutrition Center (P.J., J.S.), Boston, Mass.
ORCID: Wilson, Peter W.F.
Pencina, Michael
Jacques, Paul
Selhub, Jacob
Venue: Circulation: Cardiovascular Quality and Outcomes
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2008-11
Volume: 1
Issue: 2
Pages: 92-97
ISSN: 1941-7705 (ISSN-L)
1941-7713
DOI: 10.1161/circoutcomes.108.831198
PMC: PMC3033831
OpenAlex: W2144684988
Cited by: 299
References: 38
Citations by year: 2026: 4 · 2025: 14 · 2024: 3 · 2023: 13 · 2022: 8 · 2021: 16 · 2020: 6 · 2019: 5 · 2018: 19 · 2017: 12 · 2016: 20 · 2015: 15 · 2014: 21 · 2013: 18 · 2012: 36
FWCI: 29.86
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Circulation Cardiovascular Quality and Outcomes (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: School of Medicine, Boston University
Centre International de Recherche sur le Cancer
National Institutes of Health (n01hc25195-41-0-1)
National Heart, Lung, and Blood Institute (R01HL073272, N01‐HC25195, N01-HC-025195)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
Keywords: C-reactive protein, cardiovascular risk reclassification, coronary artery disease, cardiovascular disease, intermediate cardiovascular risk, homocysteine, risk prediction, net reclassification improvement
MeSH terms: Adult, C-Reactive Protein, Coronary Disease, Female, Follow-Up Studies, Homocysteine, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Biomarkers, Prevalence, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks